NasdaqCM - Delayed Quote • USD
Leap Therapeutics, Inc. (LPTX)
At close: 4:00 PM EDT
After hours: 4:36 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 4 | 4 | 4 | 3 |
| Avg. Estimate | -0.58 | -0.62 | -2.25 | -1.96 |
| Low Estimate | -0.64 | -0.75 | -2.78 | -2.52 |
| High Estimate | -0.56 | -0.56 | -1.78 | -1.59 |
| Year Ago EPS | -3.2 | -0.91 | -3.98 | -2.25 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 4 | 4 | 4 | 3 |
| Avg. Estimate | -- | -- | -- | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | -- |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.98 | -0.9 | -0.58 | -0.55 |
| EPS Actual | -3.2 | -0.91 | -0.51 | -0.46 |
| Difference | -2.22 | -0.01 | 0.07 | 0.09 |
| Surprise % | -226.50% | -1.10% | 12.10% | 16.40% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.58 | -0.62 | -2.25 | -1.96 |
| 7 Days Ago | -0.58 | -0.62 | -2.25 | -1.96 |
| 30 Days Ago | -0.58 | -0.62 | -2.25 | -1.96 |
| 60 Days Ago | -0.61 | -0.65 | -2.7 | -2.96 |
| 90 Days Ago | -0.61 | -0.65 | -2.25 | -2.96 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | LPTX | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 81.90% | -- | -- | 6.50% |
| Next Qtr. | 31.90% | -- | -- | 12.00% |
| Current Year | 43.50% | -- | -- | 5.30% |
| Next Year | 12.90% | -- | -- | 13.10% |
| Next 5 Years (per annum) | -2.49% | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Maintains | Baird: Outperform to Outperform | 3/19/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 3/19/2024 |
| Maintains | Mizuho: Buy to Buy | 11/20/2023 |
| Maintains | Raymond James: Outperform to Outperform | 11/14/2023 |
| Maintains | Baird: Outperform to Outperform | 8/15/2023 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 8/15/2023 |
Related Tickers
PDSB PDS Biotechnology Corporation
3.2700
+0.31%
MREO Mereo BioPharma Group plc
2.7400
-2.49%
CRVS Corvus Pharmaceuticals, Inc.
1.4500
-2.03%
DAWN Day One Biopharmaceuticals, Inc.
14.92
+12.94%
MDNAF Medicenna Therapeutics Corp.
1.8200
+30.00%
OCUL Ocular Therapeutix, Inc.
4.7450
+12.98%
AFMD Affimed N.V.
5.03
+3.07%
CLRB Cellectar Biosciences, Inc.
3.0300
+0.33%
VINC Vincerx Pharma, Inc.
0.7300
-18.59%
PIRS Pieris Pharmaceuticals, Inc.
11.72
+1.03%